Intralytix competitors

John prides himself as a builder of growing international businesses and organizations, successfully deploying both organic and M&A strategies in doing so. As President & CEO since June 2012, John has lead the turnaround and growth of Codexis Inc, the Nasdaq-listed protein engineering company based in Silicon Valley, California. Prior to Codexis, John worked in various business leadership roles for more than 22 years at Albemarle Corporation, a maker of highly engineered specialty chemicals. Spanning three successive multi-year chapters there, John lead the growth of the company’s largest, billion dollar plus global catalyst business, turned around a struggling half billion dollar fine chemicals business, and expanded and globalized Albemarle’s flame retardants business. A native of New York city, John and his family have lived widely across the USA, and also enjoyed an exciting three year assignment in Tokyo, Japan in the late 1990’s. John received a bachelor’s degree in chemical engineering from the Polytechnic Institute of New York University (now NYU) and an MBA from the Massachusetts Institute of Technology. Outside of work, John proudly boasts about his 30 year marriage, two fabulous children, and four delightful grandchildren. John also has passionately applied himself to help solve the plight of the millions of patients suffering from myalgic encephalomyelitis / chronic fatigue syndrome, and is the Board Chair for the leading patient lead organization for the cause in the US, the Solve ME/CFS Initiative (www.solvecfs.org).

Robert Kramer is a President & Chief Executive Officer at EMERGENT BIOSOLUTIONS INC., Board Member at EMERGENT BIOSOLUTIONS INC., and Interim Exec VP:Services at EMERGENT BIOSOLUTIONS INC. and is based in Lansing, Michigan. He has experience at PHARMACIA CORP and has worked as Pres:Biosciences Div at EMERGENT BIOSOLUTIONS INC., Consultant at EMERGENT BIOSOLUTIONS INC., and President at Emergent Biodefense Ops Lansg. Robert works or has worked as Chief Executive Officer at Emergent Biodefense Operations. He studied at WESTERN KENTUCKY UNIVERSITY between 1980 and 1983 and Clemson University between 1975 and 1979.

Mr. Enyedy joined ImmunoGen as President and Chief Executive Officer in 2016, bringing over twenty-five years of combined general management, business development, and legal experience in the biotechnology industry. Prior to ImmunoGen, he served as Executive Vice President and Head of Corporate Development for Shire plc leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of Akebia Therapeutics, Inc. and The American Cancer Society of Eastern New England. He previously served on the Board of Directors of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.

Douglas 'Doug' Ingram is a CEO and President at SAREPTA THERAPEUTICS, INC.; Board Member at SAREPTA THERAPEUTICS, INC.; and Board Member at Relay Therapeutics Inc and is based in Irvine, California. He has worked as Assistant General Counsel at Actavis, President at Actavis, and Board Member at Volcom. Douglas works or has worked as BOARD MEMBER at Allergan Foundation and Board Member at Pacific Life. He studied at James E Rogers College of Law until 1988, Arizona State University between 1980 and 1985, and University of Arizona.

Joe Turgeon is a President, COO at SPECTRUM PHARMACEUTICALS INC.

John Gill works at Tetralogic Pharmaceuticals and a CEO at Tetralogic Pharmaceuticals and is based in Devon, Pennsylvania. He has worked as Director and Chief Operating Officer at 3-DIMENSIONAL PHARMACEUTICALS, INC.. John attended Rutgers University—Camden between 1973 and 1975 and Transylvania University between 1969 and 1971.